Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

Research and Markets: Abilify (Aripiprazole) Major Depressive Disorder Drug Report - Forecast and Market Analysis to 2023


Research and Markets ( has announced the addition of the "Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Abilify (aripiprazole) is an atypical antipsychotic indicated for use as an adjunctive treatment for MDD in patients who have not adequately responded to antidepressant therapy in the US. Abilify is available in the 5EU, Japan, and Australia, but is not indicated for the treatment of MDD, and as such, it is being used as an off-label treatment, as validated by our primary research survey in January 2014.


  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abilify including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abilify for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Abilify (Aripiprazole)

7 Appendix

For more information visit


Rate this press release
3 stars


Add to favourites icon Add to favourites